Follow
Reda G. yousef
Reda G. yousef
PhD , Faculty of Pharmacy, Al-Azhar University
Verified email at azhar.edu.eg
Title
Cited by
Cited by
Year
Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: In vitro anticancer and VEGFR-2 inhibitory effects
EB Elkaeed, RG Yousef, H Elkady, IMM Gobaara, BA Alsfouk, DZ Husein, ...
Molecules 27 (14), 4606, 2022
742022
Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation
K El-Adl, HM Sakr, RG Yousef, ABM Mehany, AM Metwaly, ...
Bioorganic Chemistry 114, 105105, 2021
622021
New quinoxaline-2 (1 H)-ones as potential VEGFR-2 inhibitors: Design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations
RG Yousef, HM Sakr, IH Eissa, ABM Mehany, AM Metwaly, ...
New Journal of Chemistry 45 (36), 16949-16964, 2021
612021
The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches
EB Elkaeed, RG Yousef, H Elkady, IMM Gobaara, AA Alsfouk, DZ Husein, ...
Processes 10 (7), 1391, 2022
382022
Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: Virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic …
RG Yousef, A Ibrahim, MM Khalifa, WM Eldehna, IMM Gobaara, ...
Journal of enzyme inhibition and medicinal chemistry 37 (1), 1389-1403, 2022
342022
(E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth …
RG Yousef, H Elkady, EB Elkaeed, IMM Gobaara, HA Al-Ghulikah, ...
Molecules 27 (22), 7719, 2022
332022
New theobromine derivative as apoptotic anti-triple-negative breast cancer targeting EGFR protein: CADD story
IH Eissa, RG Yousef, H Elkady, EB Elkaeed, DZ Husein, IM Ibrahim, ...
Journal of Molecular Structure 1294, 136336, 2023
252023
New Anticancer Theobromine Derivative Targeting EGFRWT and EGFRT790M: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies
EB Elkaeed, RG Yousef, H Elkady, AA Alsfouk, DZ Husein, IM Ibrahim, ...
Molecules 27 (18), 5859, 2022
252022
Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation
F Ran, W Li, Y Qin, T Yu, Z Liu, M Zhou, C Liu, T Qiao, X Li, RG Yousef, ...
Oxidative medicine and cellular longevity 2021, 1-21, 2021
242021
Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies
RG Yousef, A Elwan, IMM Gobaara, ABM Mehany, WM Eldehna, ...
Journal of Enzyme Inhibition and Medicinal Chemistry 37 (1), 2206-2222, 2022
232022
In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl)naphthalene-2-ol derivative
EB Elkaeed, RG Yousef, H Elkady, ABM Mehany, BA Alsfouk, DZ Husein, ...
Journal of Biomolecular Structure and Dynamics 41 (16), 7986-8001, 2023
212023
Discovery of new VEGFR-2 inhibitors: design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies
EB Elkaeed, RG Yousef, MM Khalifa, A Ibrahim, ABM Mehany, ...
Molecules 27 (19), 6203, 2022
182022
A new anticancer semisynthetic theobromine derivative targeting EGFR protein: CADDD study
IH Eissa, RG Yousef, H Elkady, AA Alsfouk, BA Alsfouk, DZ Husein, ...
Life 13 (1), 191, 2023
112023
A New Theobromine-Based EGFRWT and EGFRT790M Inhibitor and Apoptosis Inducer: Design, Semi-Synthesis, Docking, DFT, MD Simulations, and In Vitro …
EB Elkaeed, RG Yousef, H Elkady, AA Alsfouk, DZ Husein, IM Ibrahim, ...
Processes 10 (11), 2290, 2022
112022
Design, synthesis, in silico and in vitro studies of new immunomodulatory anticancer nicotinamide derivatives targeting VEGFR-2
RG Yousef, WM Eldehna, A Elwan, AS Abdelaziz, ABM Mehany, ...
Molecules 27 (13), 4079, 2022
112022
Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach
IH Eissa, RG Yousef, EB Elkaeed, AA Alsfouk, DZ Husein, IM Ibrahim, ...
Plos one 18 (3), e0282586, 2023
92023
Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers
IH Eissa, RG Yousef, H Elkady, EB Elkaeed, AA Alsfouk, DZ Husein, ...
Computational Biology and Chemistry 107, 107953, 2023
82023
A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies
IH Eissa, RG Yousef, H Elkady, EB Elkaeed, AA Alsfouk, DZ Husein, ...
ChemistryOpen 12 (10), e202300066, 2023
62023
New quinoxalin‐2(1H)‐one‐derived VEGFR‐2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies
K El‐Adl, HM Sakr, RG Yousef, ABM Mehany, HS Abulkhair, IH Eissa
Archiv der Pharmazie 355 (7), 2200048, 2022
62022
Anti-breast cancer potential of a new xanthine derivative: in silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies
IH Eissa, RG Yousef, H Elkady, EB Elkaeed, BA Alsfouk, DZ Husein, ...
Pathology-Research and Practice 251, 154894, 2023
52023
The system can't perform the operation now. Try again later.
Articles 1–20